SCHEMBL4765936

SCHEMBL4765936

OC[C@@H](Nc1cc(-c2ccccc2)nc(-c2ccccn2)n1)[C@@H](O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
SLC2A1 P11166 1/20 0.41
ADORA1 P30542 7/20 0.40
ADORA3 P0DMS8 6/20 0.40
ADORA2A P29274 6/20 0.40
TRPV3 Q8NET8 1/20 0.39
SLC10A1 Q14973 1/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
FFAR1 O14842 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37
TSHR P16473 3/20 0.37
ADORA2B P29275 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771872 0.76 CYP2A6 (0.45) CYP1A2ADORA1ADORA3ADORA2AKMT2A
SCHEMBL18292406 0.71 MAPK14 (0.54) CYP1A2FFAR1
SCHEMBL4775017 0.71 CYP2A6 (0.44) CYP1A2KDM4EKMT2AHIF1ATSHR
SCHEMBL4773536 0.71 CYP2A6 (0.44) CYP1A2KDM4EKMT2AHIF1ATSHR
SCHEMBL4773513 0.71 CYP2A6 (0.44) CYP1A2KDM4EKMT2AHIF1ATSHR
SCHEMBL18698106 0.71 KDM4E (0.68) CYP1A2ADORA1ADORA2AKDM4ETDP1
SCHEMBL4766345 0.70 CYP2A6 (0.46) CYP1A2SLC2A1TDP1KMT2AHIF1A
SCHEMBL4774839 0.70 DYRK1A (0.51) CYP1A2ADORA1ADORA2ATSHRNPC1
SCHEMBL31747070 0.70 PPP1CA (0.62) CYP1A2SLC2A1KMT2AHIF1ANPC1
SCHEMBL7834400 0.69 MAPK14 (0.55) SLC2A1ADORA1ADORA3ADORA2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed